Earlier studies have demonstrated that the acute and chronic inhibition of sEH activity increases EET levels, lowers arterial blood pressure, and perfects against end-organ damage associated with renal and cardiovascular diseases [7,12,14,20]. Here, EPHX2 is linked to cardiovascular disorder.